Approach to interpreting common laboratory pathology tests in transgender individuals

AS Cheung, HY Lim, T Cook, S Zwickl… - The Journal of …, 2021 - academic.oup.com
Context As the number of transgender (trans) people (including those who are binary and/or
nonbinary identified) seeking gender-affirming hormone therapy rises, endocrinologists are …

Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults

SJ Iwamoto, J Defreyne, C Kaoutzanis… - Therapeutic …, 2023 - journals.sagepub.com
As the transgender and gender diverse (TGD) population ages, more transfeminine and
transmasculine individuals present to clinic to initiate or continue their gender-affirming care …

Erythrocytosis in a large cohort of trans men using testosterone: a long-term follow-up study on prevalence, determinants, and exposure years

MC Madsen, D van Dijk, CM Wiepjes… - The Journal of …, 2021 - academic.oup.com
Context Erythrocytosis is a known side effect of testosterone therapy that can increase the
risk of thromboembolic events. Objectives To study the prevalence and determinants in the …

Approach to the patient: hormonal therapy in transgender adults with complex medical histories

SJ Iwamoto, MS Rothman, G T'Sjoen… - The Journal of Clinical …, 2024 - academic.oup.com
While endocrinologists continue to initiate gender-affirming hormone therapy (GAHT) in
healthy transgender and gender diverse (TGD) patients, they may also encounter more TGD …

Approach to the patient: Pharmacological management of trans and gender-diverse adolescents

MA O'Connell, TP Nguyen, A Ahler… - The Journal of …, 2022 - academic.oup.com
Internationally, increasing numbers of children and adolescents with gender dysphoria are
presenting for care. In response, gender-affirming therapeutic interventions that seek to align …

Erythrocytosis Is Rare With Exogenous Testosterone in Gender-Affirming Hormone Therapy

N Krishnamurthy, DJ Slack, M Kyweluk… - The Journal of …, 2024 - academic.oup.com
Context Studies have found a variable incidence of erythrocytosis among people using
testosterone as part of gender-affirming hormone therapy (GAHT). Objective To examine the …

[HTML][HTML] A review of gender-affirming hormone therapy for transgender and gender diverse adults in South Korea

OH Jeong-Won, Y Yun, ES Lee - Journal of Menopausal Medicine, 2022 - ncbi.nlm.nih.gov
Recently, gender-affirming hormone therapy for gender incongruence has become an issue
in various countries and organizations with various guidelines. In South Korea, several …

Hemostatic considerations for gender affirming care

K Garland, E Mullins, RS Bercovitz, V Rodriguez… - Thrombosis research, 2023 - Elsevier
Gender dysphoria or gender incongruence is defined as “persons that are not satisfied with
their designated gender”[1]. The awareness and evidence-based treatment options …

The Utility of Serum Free Testosterone Concentrations in Monitoring Gender-Affirming Testosterone Therapy in Obese Transmasculine Youth

JM Carswell, E Barrera, E Liu, SA Roberts - Transgender Health, 2024 - liebertpub.com
Purpose: This study aimed to explore the use of serum free testosterone concentrations in
transmasculine patients as a more reliable indicator of gender-affirming testosterone therapy …

Gender‐affirming hormone therapy for transgender and gender‐diverse adults in Australia

BJ Nolan, AS Cheung - Internal Medicine Journal, 2024 - Wiley Online Library
Gender‐affirming hormone therapy (GAHT) is used by many transgender and gender‐
diverse adults to align physical characteristics with their gender identity, reduce gender …